Mass’ Eaton Apothecary signs agreement for Med-eMonitor
ROCKVILLE, Md. InforMedix Holdings, developer of the Med-eMonitor System for medication adherence and disease management, has signed a distribution agreement with Eaton Apothecary.
According to the agreement, Eaton Apothecary will distribute the Med-eMonitor System in its pharmacies in Weston and Newton Mass., as a trial that could potentially expand to more of its stores once proven successful.
InforMedix’s Med-eMonitor System is an interactive “smart pillbox” for medication adherence, monitored by healthcare professionals at 24/7 call centers. In addition to storing medications and tracking patient adherence to their health plans, the Med-eMonitor provides healthcare professionals with real-time alerts when patients miss their medications or if their health declines. InforMedix believes that the device promises to be especially helpful for members of the baby boomer generation who are taking care of the elderly as well as young children.
FDA approves label changes for Accutane and its generics
The Food and Drug Administration has approved label changes to Roche’s acne medication Accutane and its generic isotretinoin, manufactured by Barr Laboratories, Genpharm/Mylan Pharmaceuticals and Ranbaxy Laboratories.
The label changes were made to improve the management of the iPledge pregnancy risk management program. Pregnant women are not allowed to take the medication due to risk of birth defects.
Roche, who proposed the changes, said they are intended to enhance the flexibility of the iPledge program, reduce interruptions in treatment and reduce the burden on patients, prescribers and pharmacies, thereby making the program more consistent with the way prescribers function.
The changes are planned to go into effect on Dec. 2.
FDA approves Ixempra for breast cancer
WASHINGTON The Food and Drug Administration has approved Bristol-Myers Squibb’s Ixempra monotherapy for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes and capecitabine.
The FDA has also granted approval of Ixempra in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to an anthracycline and a taxane or whose cancer is taxane-resistant and for whom further anthracycline therapy is contraindicated.
BMS anticipates Ixempra will be available soon.